The U.S. Food and Drug Administration has cleared the first gene therapy in American history designed to restore hearing for people born deaf — and the company behind it, New York–based Regeneron Pharmaceuticals, has committed to providing the treatment at no cost to clinically eligible patients in the United States. The decision, announced on April 23, 2026, was hailed across the field as a generational milestone in the treatment of hearing loss and the first FDA-approved example of a gene therapy capable of restoring a neurosensory function to normal levels.
The therapy, branded Otarmeni (lunsotogene parvec-cwha), is a one-time, surgically delivered treatment for patients with severe-to-profound hearing loss caused by mutations in the OTOF gene. It received accelerated approval through the FDA’s National Priority Voucher program, a fast-track pathway intended to speed transformative therapies to market.
How the Therapy Works
OTOF mutations disrupt the production of otoferlin, a protein that the inner ear’s hair cells use to transmit sound signals from the ear to the brain. Without functional otoferlin, the hair cells themselves remain intact but cannot communicate auditory information, which leads to profound hearing loss from birth.
Otarmeni delivers a functional copy of the OTOF gene through an adeno-associated virus (AAV) vector, infused directly into the cochlea under general anesthesia. The surgical approach is similar to a cochlear implant procedure, but the goal is fundamentally different. Rather than bypassing the damaged hearing pathway with electronic stimulation, the therapy repairs it at the genetic level. A proprietary Myo15 cell-specific promoter restricts expression to the inner hair cells that normally produce otoferlin, keeping the therapeutic effect targeted.
Eligible patients must have preserved outer hair cell function and no prior cochlear implant in the affected ear.
The CHORD Trial Results
The accelerated approval is based on results from the pivotal CHORD trial, an open-label, multicenter Phase 1/2 study of 20 participants ranging in age from 10 months to 16 years. Half received the therapy in one ear, half in both ears.
The data drove the decision. Eighty percent of trial participants (16 of 20) experienced hearing improvements at a threshold of 70 decibels or better at 24 weeks, achieving the trial’s primary endpoint. One additional participant reached that threshold by week 48. With longer follow-up, 42% of participants achieved normal hearing levels, including the ability to perceive whispers, and the hearing gains have held for at least two years so far.
For most patients, the changes began within weeks of the procedure, with the quality of hearing improving in the months that followed. One mother, whose son was treated as part of the broader trial program, described the moment he heard her voice for the first time as the most surreal moment a mother can feel.
Why Regeneron Is Providing the Therapy Free
One-time gene therapies for rare conditions are often priced at several million dollars per patient, a structure designed to recoup the substantial research, development, and manufacturing costs that go into a single approval. Regeneron has taken a different path with Otarmeni.
The company announced that it will provide the therapy at no cost to clinically eligible patients in the United States. Out-of-pocket costs may still apply for the administration procedure itself, since the surgery and anesthesia are billed through hospitals and clinics. Regeneron has also said it plans to file for regulatory approval in additional countries but has not yet committed to similar free-access arrangements outside the U.S.
The decision is unusual within the broader gene therapy market and has been viewed as a goodwill move tied to the small patient population, the high public visibility of the approval, and the company’s broader genetic medicines pipeline. Otarmeni is Regeneron’s first approved genetic medicine, and the company has used the approval as a proof point for its capabilities in the field.
A Small Patient Population, A Large Scientific Signal
The condition Otarmeni treats is rare. OTOF-related hearing loss affects an estimated 50 newborns each year in the United States and accounts for roughly 1% to 3% of cases of genetic hearing loss at birth.
Despite the small immediate patient pool, researchers and clinicians across the hearing-loss field have characterized the approval as the start of a new era. Zheng-Yi Chen, an associate scientist at Mass Eye and Ear in Boston who was not involved in the development of Otarmeni, told NPR that the approval represents the first new drug for hearing loss in history.
The broader implication is that a successful gene therapy approval in the auditory space is expected to spur additional research investment, expand treatment options for other forms of genetic hearing loss, and accelerate the development of therapies that can repair sensory function rather than just compensate for its loss.
What Happens Next
Regeneron has said the therapy should be available within weeks at qualified treatment centers in the U.S. Continued approval may be contingent upon longer-term assessment of hearing durability and verification of treatment effects on speech development and quality-of-life measures.
For families across the country who have received an OTOF diagnosis, the path forward now includes an option that did not exist a week ago. For the field of genetic medicine, the approval represents a tangible answer to a question scientists have been working on for decades: whether the inner ear can be restored at the genetic level.
A New York-based company has just demonstrated that the answer is yes.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients and families considering Otarmeni or any gene therapy should consult with qualified medical professionals about eligibility, risks, and individual treatment options. Clinical trial results and approval details cited reflect publicly available information from the FDA and Regeneron Pharmaceuticals as of April 23, 2026.
